Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-415 in MMG49-positive relapsed/refractory multiple myeloma
jRCT2033200278Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Feb 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OPC-415 in multiple myeloma (MM), sponsored by Otsuka Pharmaceutical Co., Ltd. Started Feb 2021; status: completed.
02
Drugs
OPC-415
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2033200278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033200278.